Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

115results about "Cytochromes" patented technology

Compositions and methods for treating malaria with cupredoxin and cytochrome

The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by P. falciparum. The invention provides isolated peptides that are variants, derivatives or structural equivalents of cupredoxins or cytochrome c, and compositions comprising cupredoxins and / or cytochrome c, or variants, derivatives or structural equivalents thereof, that are useful for treating or preventing malaria infection in mammals. Further, the invention provides methods to treat mammalian patients to prevent or inhibit the growth of malarial infection in mammals. The invention also provides methods to prevent the growth of malaria infection in insect vectors.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS

6-Monoacetylmorphine derivatives useful in immunoassay

InactiveUS20070142628A1Sugar derivativesSerum albumin6-MonoacetylmorphineMorphine
Analogs of 6-monoacetyl morphine (6-MAM) are described. These include analogs derivatized at either the C-3 position, the C-6 position, or the nor position of the molecule. These analogs allow for elaboration with linkers terminated by a functional group such as an activated ester, the functional groups being useful for attaching the molecule to other entities such as proteins, polysaccharides, and reporter groups.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC

Electrochemical affinity biosensor system and methods

The present invention provides novel osmium-based electrochemical species for the detection of wide variety of analytes using immunological techniques. The present invention also provides diagnostic kits and test sensors supporting electrode structures that can be used with the osmium-based electrochemical species. The test sensor can be fabricated to support interdigitated arrays of electrodes that have been designed to provide amplification of the electrical signal amplification desired to analyze analytes that may be present at low concentrations.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC

Preparation method of chitosan-silicon dioxide compound hollow microballoon and application thereof

The invention relates to a chitosan-silicon dioxide compound hollow microballoon, tetraethoxysilane is poly-condensed and deposited on the surface of a chitosan-polyacrylic acid microballoon through hydrolyzation, so as to obtain the chitosan-silicon dioxide compound hollow microballoon with macro pore and meso pore structures, the average grain diameter is 50-200nm, wherein the molecular weight of chitosan is 10000-200000, and deacetylation is 70-95 percent.
Owner:NANJING UNIV

Protein electron mediator

The problem to be resolved is to provide an electron mediator and a fusion body with high affinity with an enzyme, a measuring method using extracellular secretion type cytochrome and an enzyme, an electrode, and a sensor.The present invention relates to an electron mediator for glucose oxidoreductase comprising extracellular secretion type cytochrome, a fusion body in which the electron mediator is fused with glucose oxidoreductase, a composition for glucose measurement including the electron mediator or fusion body, a gene encoding a new extracellular secretion type cytochrome, and a measurement method using extracellular secretion type cytochrome and an enzyme, an electrode, and a sensor.
Owner:IKEDA SHOKKEN KK

Novel fusion partners for the purpose of crystallizing g-protein coupled receptors

GPCR-fusion partner proteins comprising G protein coupled receptors (GPCRs) of GPCRs and fusion partners such as rubredoxin, cytochrome b562 RIL (Bril, bRIL, BRIL), T4 lysozyme C-terminal fragment (Cterm-T4L), flavodoxin, or xylanase either substituted for some or all of the third intracellular loop of the GPCR between the fifth and sixth helix of the GPCR are described or attached to an terminus or C terminus of the GPCR. GPCR-fusion partner proteins in crystalline form, optionally of a quality suitable for x-ray crystallographic structure determination of the GPCR, are described. Methods of using fusion partners in GPCR-fusion partner proteins to support crystallization of GPCR-fusion partner proteins for x-ray crystallographic structure determination of the GPCR, are described. Methods of identifying other suitable fusion partners through screening of protein data banks are also described.
Owner:THE SCRIPPS RES INST

Peptide conjugates

The present invention relates to a method for synthesizing peptide conjugates comprising a functional peptide, cyclic by means of a lactam bridge; a sulfur-linker bound to said cyclic peptide, wherein said sulfur-linker comprises sulfur or a sulfur-reactive site. The invention further relates to a method for synthesizing peptide-effector conjugates. The invention also relates to peptide conjugates. Peptide conjugates according to the present invention have improved half-life and increased availability at the active site and they are useful in cell targeting and tumor diagnosis and therapy.
Owner:KARYON CTT

Enzyme@ZIF-8@Fe3O4 magnetic nanoenzyme reactor and preparation method thereof

The invention discloses an enzyme@ZIF-8@Fe3O4 magnetic nanoenzyme reactor and a preparation method thereof. A denovo method is used for citric acid modification on the surface of the Fe3O4 magnetic nanometer particles; then, ZIF-8 is coated to form a ZIF-8@ZIF-8@Fe3O4 core-shell structure; meanwhile, chloroperoxidase, horse radish peroxidase or cytochrome C are immobilized onto ZIF-8 in the ZIF-8 coating process, so that the enzyme@ZIF-8@Fe3O4 magnetic nanoenzyme reactor with the magnetic separation effect is obtained, wherein the particle diameter of the citric acid modified Fe3O4 magnetic nanometer particles is 250 to 300 nm; the thickness of the ZIF-8 shells of the surface coated immobilization enzyme is 50 to 80 nm. The preparation method provided by the invention is simple and convenient; the thermal stability and the acid and base stability of the obtained enzyme@ZIF-8@Fe3O4 magnetic nanoenzyme reactor are obviously improved through being compared with that of free enzyme; good repeated use performance is realized.
Owner:SHAANXI NORMAL UNIV

Tumor-specific P450 protein

The discovery that Cyp1B1 protein is detectable in a wide range of human cancers of different histogenetic types, but is not detectable in non-cancerous tissues, gives rise to diagnostic methods for detecting tumors based on this protein as a marker, and to the possibility of tumor therapies involving the protein. A diagnostic method may include the steps of: (a) obtaining from a patient a tissue sample to be tested for the presence of cancer cells; (b) producing a prepared sample in a sample preparation process; (c) contacting the prepared sample with an antibody that reacts with human Cyp1B1 protein; and (d) detecting binding of the antibody to CYP1B1 protein in the prepared sample.
Owner:ABERDEEN UNIV OF +1

Protein-Immobilized membrane, method for immobilization of protein, enzyme-immobilized electrode, and biosensor

The present invention relates to a protein-immobilized membrane (14) including a cell membrane homologous layer (14A) and a protein (14B) immobilized to the cell membrane homologous layer (14A), where the protein contains cytochrome or a cytochrome complex. The present invention also relates to a method for forming a protein-immobilized membrane (14), and an enzyme-immobilized electrode and a biosensor (X1) provided with a protein-immobilized membrane (14). Preferably, the cell membrane homologous layer (14A) may contain a phospholipid polymer, and the protein (14B) may be CyGDH including an α subunit having a glucose dehydrogenase activity and cytochrome C having a function of electron transfer.
Owner:ARKRAY INC

Application of herbicide tolerance protein

The invention relate to application of herbicide tolerance protein. A weed control method includes the step of applying herbicide with an effective dosage of pyrazosulfuron ethyl to the plant growth environment of at least one transgenic plant, wherein genomes of the transgenic plants have nucleotide sequences for encoding thifensulfuron methyl hydrolase, and the transgenic plants have weak plant damage and / or increased plant yield compared with other plants without nucleotide sequences for encoding thifensulfuron methyl hydrolase. Thifensulfuron methyl hydrolase is disclosed for the first time and presents high tolerance for the pyrazosulfuron ethyl herbicide, and the plants with nucleotide sequences for encoding thifensulfuron methyl hydrolase have strong tolerance for the pyrazosulfuron ethyl herbicide and at least can bear 1-fold field concentration, and therefore wide application prospects are achieved for plants.
Owner:BEIJING DABEINONG BIOTECHNOLOGY CO LTD

Cytochrome-fused glucose dehydrogenase and glucose measurement method

A cytochrome b-glucose dehydrogenase fusion protein having modified electron transfer properties, and a glucose measurement method and measuring kit using the cytochrome b-glucose dehydrogenase fusion protein are provided. Provided are a cytochrome b-glucose dehydrogenase fusion protein in which glucose dehydrogenase having homology with SEQ ID NO: 1 or SEQ ID NO: 4 and cytochrome b are linked together, as well as a glucose measurement method, a measurement reagent kit and a sensor using the cytochrome b-glucose dehydrogenase fusion protein. The cytochrome b-glucose dehydrogenase fusion protein of the present invention has modified electron transfer properties, and can be used for measuring glucose in the presence of a free-form mediator in reduced concentration or in the absence of a free-form mediator, and can be used, for example, in continuous glucose monitoring.
Owner:KIKKOMAN CORP

Crystal structure of cytochrome P450

The invention provides the crystal structure of the cytochrome P450 3A4 protein molecule. The structure is set out in Tables 1-4. The structure may be used in to model the interaction of compounds such as pharmaceuticals with this protein, and to determine the structure of related cytochrome P450 molecules.
Owner:ASTEX THERAPEUTICS LTD

Crystal structure of cytochrome P450

The invention provides the crystal structure of the cytochrome P450 3A4 protein molecule. The structure is set out in Table 5. The structure may be used in to model the interaction of compounds such as pharmaceuticals with this protein, and to determine the structure of related cytochrome P450 molecules.
Owner:ASTEX THERAPEUTICS LTD

Crystals of cytochrome P450 2C9, structures thereof and their use

The present invention provides cytochrome 2C9 proteins which have been modified to introduce a proline residue at positions 220 or 222 of the wild type sequence which can be crystallised to provide high resolution structures. The structures may be used for homology modelling of other cytochrome P450 structures such as 2C8, 2C18 and 2C19, and for analysis of the interaction of ligands with P450.
Owner:ASTEX THERAPEUTICS LTD

Artificial mammalian chromosome

It is intended to provide an artificial mammalian chromosome which is stably held in mammalian cells and allows efficient expression of a target gene carried thereby. Namely, a first cyclic vector containing a mammalian centromere sequence and a selection marker gene and a second cyclic vector containing a functional sequence are transferred into mammalian host cells. Then transformed cells are selected by using the above-described selection marker gene and cells holding an artificial mammalian chromosome are selected from among the transformed cells thus selected. Thus, it is possible to construct an artificial mammalian chromosome which has a mammalian replication origin, the mammalian centromere sequence and the functional sequence, is in a cyclic form, can be replicated in mammalian cells, extrachromosomally held in the host cells and transferred to daughter cells in cell division.
Owner:JAPAN SCI & TECH CORP

A kind of purification process of cytochrome c

The invention discloses a new process for purifying cytochrome C, which comprises the following steps: (1) extracting cytochrome C coarse extract from animal organs or yeasts; (2) adding an inorganic salt into the coarse extract to perform salting, standing, centrifuging and removing settled proteins, and collecting supernate; (3) adding buffer solution to regulate the inorganic salt concentration in the supernate to 20 to 35 percent, and purifying the supernate by using front-end hydrophobic chromatography, namely continuously loading the obtained solution onto a hydrophobic chromatographic column which is balanced by inorganic salt solution at a concentration of 20 to 35 percent in advance and collecting penetration solution; and (4) washing the chromatographic column by using the inorganic salt solution at a concentration of 20 to 35 percent till a stable light absorbance, collecting the efflux of the chromatographic column, mixing the efflux of the chromatographic column with penetration solution, and purifying to obtain cytochrome C. In the invention, the operation is simple and convenient, the separation and purification effect is good, the yield is high and cost is low.
Owner:NORTHWEST UNIV(CN)

Transgenic animals for assessing drug metabolism and toxicity

The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans.
Owner:ITI LIFE SCI +1

Crystals of cytochrome P450 2C9, structures thereof and their use

The present invention provides cytochrome 2C9 proteins which have been modified to introduce a proline residue at positions 220 or 222 of the wild type sequence which can be crystallised to provide high resolution structures. The structures may be used for homology modelling of other cytochrome P450 structures such as 2C8, 2C18 and 2C19, and for analysis of the interaction of ligands with P450.
Owner:ASTEX THERAPEUTICS LTD

Super respiratory chain compound protein

The invention relates to a mammalian cell super respiratory chain compound protein and in particular to a super respiratory chain compound protein of a high atom resolution electron cryomicroscopy structure, and a preparation method of the protein. By adopting the protein structure, the respiratory action mechanism of mammalian animals and diseases related to respiratory action can be further studied.
Owner:TSINGHUA UNIV

Crystals of cytochrome P450 2C9, structures thereof and their use

The present invention provides co-crystals of cytochrome P450 2C9 proteins and a ligand such as warfarin which has been crystallised to provide a high resolution structure. The structure may be used for homology modelling of other cytochrome P450 structures such as 2C8, 2C18 and 2C19, and for analysis of the interaction of ligands with P450.
Owner:ASTEX THERAPEUTICS LTD

New method for preparing cytochrome C

The invention discloses a method for extracting cytochrome C, which comprises the following steps of: using the cardiac muscle of a mammal as a raw material; extracting the cytochrome C by adopting an extraction method using an aluminum sulfate solution, wherein the concentration of aluminum sulfate in the extraction process is controlled to be between 0.1 and 10 percent, the volume of the aluminum sulfate solution is controlled to be 1 to 5 times that of the cardiac muscle, the extraction pH value is controlled to be between 3 and 6, the reaction temperature is controlled to be between 0 and 30 DEG C, and the extraction time is controlled to be 1 to 4 hours; and performing adsorption elution to finally obtain the cytochrome C. The method has the characteristics of low cost, simple steps, mild extraction condition, fewer impurities, pollution-free reactants, and suitability for industrial mass production.
Owner:YANTAI DONGCHENG PHARMA GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products